Under the deal IOI Loders Croklaan will continue to manufacture the lipid described as possessing a “special triglyceride structure that matches the one found in mother’s milk very closely”.
Kerry will focus on marketing activities along with product development at its €100m Global Technology & Innovation Centre in Ireland.
Betapol’s strongest markets are Europe and Asia.
“There are many complementary areas and synergies between our two companies,” said IOI Loders Croklaan CEO Julian Veitch in a statement.
He said as a partner Kerry offered “ world-class infant nutrition innovation and solutions that are founded in science.”
Kerry’s nutrition president Michael O’Neill added its new partner “has a vertically integrated supply chain and is the world’s most experienced and trusted producer of OPO-type fats.”
OPO is a lipid form found in breast milk.
“Betapol has been developed in order to overcome the problems associated with poor fatty acid absorption from infant formula and the negative consequences of this on energy supply, stool consistency and bone development,” Loders Croklaan said previously.
NutraIngredients’ Omega-3 forum – April 8. Head winds & trade wins
Tap the latest from the industry and scientific frontiers in the ever-changing and expansive omega-3 space in a no-holds barred debate on April 8.
It’s a €25bn sector but can it keep growing amid scientific and sustainability challenges? Misappropriated research? Plant v marine? Emerging v Emerged markets? Changing demographics...
Tune in to find out…simple registration available here.